𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Causes of dissociation between subjective workload measures and performance: Caveats for the use of subjective assessments

✍ Scribed by M.A. Vidulich; C.D. Wickens


Publisher
Elsevier Science
Year
1986
Tongue
English
Weight
579 KB
Volume
17
Category
Article
ISSN
0003-6870

No coin nor oath required. For personal study only.

✦ Synopsis


Dissociations between subjective workload assessments and performance were investigated. The difficulty of a Sternberg memory search task was manipulated by varying stimulus presentation rate, stimulus discernibility, value of good performance, and automaticity of performance. All Sternberg task conditions were performed both alone and concurrently with a tracking task. Bipolar subjective workload assessments were collected. Dissociations between workload and performance were found related to automaticity, presentation rate and motivation. The results were interpreted as supporting the hypothesis that the specific cognitive processes responsible for subjective assessments can differ from those responsible for performance. The potential contamination these dissociations could inflict on operational assessments was discussed.


πŸ“œ SIMILAR VOLUMES


Measures of social function and particip
Evaluating the serial use of the myelofi
✍ Ruben A. Mesa; Hagop Kantarjian; Ayalew Tefferi; Amylou Dueck; Richard Levy; Kri πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 264 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: Symptomatic burden from constitutional symptoms, anemia, and splenomegaly‐related symptoms are common and morbidity inducing in patients with myelofibrosis (MF). The authors previously developed a MF‐specific instrument for capturing the burden of MF‐associated disease‐r

The Disease Activity Score is not suitab
✍ Frederick Wolfe; Kaleb Michaud; Theodore Pincus; Daniel Furst; Edward Keystone πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 218 KB πŸ‘ 2 views

## Abstract ## Objective The Disease Activity Score (DAS) is widely used in clinical trials. A DAS of 5.1 defines the level of severe rheumatoid arthritis (RA) and is the criterion for the initiation of anti–tumor necrosis factor therapy in the UK and The Netherlands. In North America, similar rul